A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial).
<p>INTRODUCTION: Malaria due to Plasmodium knowlesi is reported throughout South-East Asia, and is the commonest cause of it in Malaysia. P. knowlesi replicates every 24 h and can cause severe disease and death. Current 2010 WHO Malaria Treatment Guidelines have no recommendations for the opti...
Үндсэн зохиолчид: | Grigg, M, William, T, Dhanaraj, P, Menon, J, Barber, B, von Seidlein, L, Rajahram, G, Price, R, Anstey, N, Yeo, T |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
BMJ Group
2014
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): An open-label, randomised controlled trial
-н: Grigg, M, зэрэг
Хэвлэсэн: (2015) -
Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: An open-label, randomized, controlled trial.
-н: Grigg, M, зэрэг
Хэвлэсэн: (2016) -
Efficacy of Artesunate-mefloquine for Chloroquine-resistant
Plasmodium vivax
Malaria in Malaysia: An Open-label, Randomized, Controlled Trial
-н: Grigg, Matthew J., зэрэг
Хэвлэсэн: (2016) -
Artemether-lumefantrine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria (CAN KNOW): an open-label randomized controlled trial
-н: Grigg, M, зэрэг
Хэвлэсэн: (2017) -
Deaths due to <it>Plasmodium knowlesi</it> malaria in Sabah, Malaysia: association with reporting as <it>Plasmodium malariae</it> and delayed parenteral artesunate
-н: Rajahram Giri S, зэрэг
Хэвлэсэн: (2012-08-01)